Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Ushers Out Known DMAA, Closes Dietary Ingredient Door

This article was originally published in The Tan Sheet

Executive Summary

USPlabs says it will reformulate its DMAA supplements, although it “stands by the safety and legality” of the products. FDA says “credible science” shows DMAA is not a botanical, not a dietary ingredient and will not be accepted in an NDI notification.

You may also be interested in...

DMAA, Other Stimulants Cast Shadow Over FDA Supplement Regulation – Study

Six workout and weight loss brands contained DMAA and three other stimulants, according to a study in the Journal Clinical Toxicology. Researchers concluded consumers must be informed of risk so they know to check labels for three substances that indicate the presence of the stimulants.

Five Shanghai Suspects Charged After FDA Undercover Work On Spiked Supplements

One of the undeclared stimulant ingredients, 2-amino-6-methylheptane, or DMHA, is new on FDA's radar for violative ingredients used in products marketed as dietary supplements, while the other, 1,3-dimethylamylamine, DMAA, has long been a target of agency enforcement in the supplement sector.

BMPEA In Supplements Spells Trouble To Researchers; FDA Has Different Idea

Researchers say beta-methylphenylethylamine – BMPEA – is a synthetic stimulant and they found it in 11 of 21 supplement products labeled as containing “Acacia rigidula.” FDA also has looked at BMPEA in supplements and says there is not “a specific safety concern at this time.”

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts